During the projected period (2023-2030), it is anticipated that the global anti-venom market will expand at a CAGR of 7.00%. Antivenom is more likely to be required in places with a higher density of poisonous snakes or in locations where encounters between humans and snakes are more frequent. For Instance, in July 2022, According to Discover Magazine in UK snakebites increased in frequency. There are more than 250 species of poisonous snakes, most of which are indigenous to Asia, Africa, Latin America, and Oceania, according to the World Health Organization (WHO). The adder, grass snake, and smooth snake are the three native snake species found in the UK. In the fields of cardiovascular disease, cancer research, and neurological disease, snake venom has shown significant potential. Venom-derived pharmaceuticals, such as anti-venom, blood pressure medicines, and pain relievers, have already been created and are in use. Various significant drug discoveries and advances are attracted to the distinctive features of snake venom components.
For Instance, In November 2020, An international research group headed by researchers from the University of Bristol is developing a novel method of treating the potentially fatal snake bites that cause about 100,000 fatalities globally each year. Teams from the UK, France, Belgium, and Portugal participated in the EU-funded ADDovenom project, which aimed to develop a new type of antivenom treatment to neutralize and remove venom toxins from the bloodstream more effectively, safely, and affordably. In the US, thousands of North American Pit Viper envenomated patients now have a new treatment option, supporting RDT’s goal of bringing essential medications for uncommon disorders to market. For Instance, In April 2021 Rare Disease Therapeutics, Inc. Announces New Expanded FDA Approved Indication for Antivenom ANAVIP® for the Treatment of North American Pit Viper Envenomation. The polyvalent antivenom inefficaciously neutralizes the venom from distinct populations of the ‘big four’ snakes, as well as many other local clinically important snake species. For Instance, In August 2022, Biopharmaceutical company Bharat Serums and Vaccines (BSV) is partnering Indian Institute of Science (IISc), Bengaluru, to develop next-generation snakebite therapy in India. Another important study shows that antivenom reduces the risk of skin necrosis in patients bitten by brown recluse spiders. For Instance, In January 2023 According to Butantan Institute Brazilian researchers recently reported in PLOS Neglected Tropical Diseases shows that the problem can be solved by administering antivenom, especially if this is done within 48 hours of the incident. The overall increase in healthcare expenditure, collaboration and partnership, Expansion of distribution network, Government initiative and rising incidence of Snakebites particularly in emerging economics, has provided the necessary financial support for the procurement and distribution of anti-venom. as healthcare system improve more resources are allocated to address is Snake bite incidents, driving market growth. For Instance, In April 2023 MicroPharm announce re-establish supplies of Fav-Afrique in its current format as an equine F(ab’)2 based antivenom suitable for the treatment of Category 1 venomous African snakes.
To Request a Sample of our Report on Anti-Venom Market: https://www.omrglobal.com/request-sample/anti-venom-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
Segment Covered-
- By Species
- By Anti-Venom Type
- By Mode of Action
- By End User
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- includes Bharat Serums and Vaccines limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific corporation, Merck & Co. Inc., Pfizer Inc., BTG International Inc.
Anti-Venom Market Report Segment
By Species
- Snake
- Scorpion
- Spider
- Others (Marine animals, Insects)
By Anti-venom Type
- Polyvalent Anti-Venom
- Monovalent Anti-Venom
By Mode of Action
- Cytotoxic
- Neurotoxic
- Haemotoxic
- Cardiotoxic
- Myotoxic
- Others(Phospholipase A2 (PLA2s), hemorrhagic metalloproteinases)
By End User
- Hospitals
- Clinics
- Ambulatory Surgical Centers
A full report of Anti-venom Market available @ https://www.omrglobal.com/industry-reports/anti-venom-market
Anti-venom Market Report Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Bioclon Institute
- BTG International Inc.
- CSL Ltd.
- Flynn Pharma
- Haffkine Bio-Pharmaceutical Corp Ltd.
- Incepta Pharmaceuticals Ltd.
- Inosan Biopharma
- Instituto Vital Brazil
- MicroPharm Ltd.
- Merck & Co. Inc.
- Merck KGaA
- Pfizer Inc.
Reasons to Buy From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
